Other Clinical Trial - A Study of Baricitinib (LY3009104) in Participants

Updated 05/07/2024

Status Recruiting

Clinical Trial Summary

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Arthritis
Arthritis, Juvenile
Systemic Juvenile Idiopathic Arthritis

Clinical Trial Details

NCT number	NCT04088396
Study type	Interventional
Source	Eli Lilly and Company
Contact	There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone	1-317-615-4559
Email	ClinicalTrials.gov@lilly.com
Status	Recruiting
Phase	Phase 3
Start date	February 12, 2020
Completion date	October 27, 2025

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00891046` - An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.	Phase 3
	Completed	`NCT01304420` - Ultrasonography in Juvenile Idiopathic Arthritis	Phase 0
	Completed	`NCT02334748` - A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies	Phase 3
	Completed	`NCT01803321` - Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	Phase 1
	Completed	`NCT00144664` - Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Phase 3
	Completed	`NCT02396212` - Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA	Phase 3
	Completed	`NCT00144599` - Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	Phase 3
	Terminated	`NCT00886769` - Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)	Phase 3
	Completed	`NCT00144612` - Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	Phase 3
	Withdrawn	`NCT01676948` - An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	Phase 3
	Recruiting	`NCT05027373` - Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection	Phase 1